Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check2 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1%
- Check9 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.